Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2-metastatic breast cancer (Chloe trial)

被引：0
|
作者：
Shien, T. [1 ]
Shimomura, A. [2 ]
Uemura, Y. [3 ]
Kato, H. [4 ]
Kitada, M. [5 ]
Kikawa, Y. [6 ]
Shiba, E. [7 ]
Yoshida, T. [8 ]
Morimoto, T. [9 ]
Toyama, T. [10 ]
Aihara, T. [11 ]
Mukai, H. [12 ]
机构：
[1] Okayama Univ Hosp, Breast & Endocrine Surg, Okayama, Japan
[2] Natl Canc Ctr, Breast & Med Oncol, Tokyo, Japan
[3] Tokyo Univ Hosp, Biostat, Clin Res Support Ctr, Tokyo, Japan
[4] Teine Keijinkai Hosp, Thorac Surg, Sapporo, Hokkaido, Japan
[5] Asahikawa Med Univ, Surg, Asahikawa, Hokkaido, Japan
[6] Gen Hosp, Kobe City Med Ctr, Breast Surg, Kobe, Hyogo, Japan
[7] Osaka Breast Clin, Surg, Osaka, Japan
[8] Kanagawa Canc Ctr, Breast & Endocrine Surg, Yokohama, Kanagawa, Japan
[9] Yao Municipal Hosp, Breast Surg, Osaka, Japan
[10] Nagoya City Univ, Grad Sch Med Sci, Breast Surg, Nagoya, Aichi, Japan
[11] Keimeikai Aihara Hosp, Surg, Osaka, Japan
[12] Natl Canc Ctr Hosp East, Breast & Med Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
313TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States
    Giovanni Zanotti
    Matthias Hunger
    Julia J Perkins
    Ruslan Horblyuk
    Monique Martin
    BMC Cancer, 17
  • [42] Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer
    Kristoffer B. Kristensen
    Ida Marie Nedergaard Thomsen
    Tobias Berg
    Annette R. Kodahl
    Anders Bonde Jensen
    Breast Cancer Research and Treatment, 2021, 188 : 799 - 809
  • [43] Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2-metastatic breast cancer: WJOG11418B NEWFLAME trial
    Masuda, Jun
    Tsurutani, Junji
    Masuda, Norikazu
    Tanabe, Yuko
    Iwasa, Tsutomu
    Takahashi, Masato
    Futamura, Manabu
    Matsumoto, Koji
    Aogi, Kenjiro
    Iwata, Hiroji
    Hosonaga, Mari
    Mukohara, Toru
    Yoshimura, Kenichi
    Takano, Toshimi
    CANCER RESEARCH, 2021, 81 (04)
  • [44] Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2-Metastatic Breast Cancer
    Mayer, Erica L.
    Ren, Yue
    Wagle, Nikhil
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy D.
    Jolly, Trevor
    Riley, Elizabeth
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Sinclair, Natalie
    Faggen, Meredith
    Block, Caroline
    Ko, Naomi
    Partridge, Ann
    Chen, Wendy Y.
    Demeo, Michelle K.
    Attaya, Victoria
    Okpoebo, Amanda
    Liu, Yuan
    Gauthier, Eric
    Burstein, Harold
    Regan, Meredith
    Tolaney, Sara
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Ribociclib for post-menopausal women with HR+/HER2-advanced or metastatic breast cancer
    Zangardi, Mark L.
    Spring, Laura M.
    Blouin, Gayle C.
    Bardia, Aditya
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1169 - 1176
  • [46] The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2-metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.
    Finn, Richard S.
    Crown, John
    Lang, Istvan
    Kulyk, Sergey O.
    Schmidt, Marcus
    Patel, Ravi
    Thummala, Anu
    Bondarenko, Igor
    Randolph, Sophia
    Kim, Sindy
    Huang, Xin
    Donnelly, Erling
    Bartlett, Cynthia Huang
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Using real-world data to evaluate the performance of endocrine therapies in ER+/Her2-metastatic breast cancer patients.
    Chen, Tenghui
    Zhang, Zhaojie
    Gao, Lei
    Scholz, Catherine
    Gualberto, Antonio
    Yu, Lihua
    Yu, Kun
    CANCER RESEARCH, 2022, 82 (12)
  • [48] A phase II open-label trial to evaluate the efficacy and toxicity of erlotinib in women with metastatic, hormone receptor negative, and HER2-negative breast cancer
    Rao, R. D.
    Siziopikou, K. P.
    Cobleigh, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [49] Comparative effectiveness of everolimus versus chemotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US.
    Li, Nanxin
    Hao, Yanni
    Xie, Jipan
    Lin, Peggy L.
    Koo, Valerie
    Ohashi, Erika
    Wu, Eric Qiong
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    Yardley, Denise A.
    Liggett, William
    Mainwaring, Mark
    Castrellon, Aurelio
    Blakely, Laura
    Hemphill, Brian
    Anz, Bertrand, III
    Young, Robyn R.
    Shastry, Mythili
    DeBusk, Laura M.
    Hainsworth, John D.
    Burris, Howard A., III
    CLINICAL BREAST CANCER, 2020, 20 (02) : 89 - 97
12345